Navigation Links
Nephros Rights Offering Registration Statement Declared Effective
Date:1/31/2011

rged to read the prospectus carefully when available.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration (HDF) system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros ESRD products are sold and distributed throughout Europe.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Nephros's DSUs are being evaluated at several major U.S. medical centers for infection control. The DSU has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (t
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... , Nov. 23, 2014 Anthera Pharmaceuticals, ... Paul F. Truex , President and Chief Executive ... Annual Piper Jaffray Healthcare Conference. Anthera ... at the Palace Hotel in New York ... Anthera Pharmaceuticals is a biopharmaceutical company focused ...
(Date:11/22/2014)... -- Sprout Pharmaceuticals today announced positive preliminary results from a Phase ... up to 200 mg at bedtime had no next-day impairment ... th Annual Fall Scientific Meeting of the Sexual Medicine ... Miami . The Phase 1 driving ... and the Formal Dispute Resolution that was filed in December ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 29, 2011 Breast cancer patients and their families ... (FDA) decision to remove the anti-cancer drug Avastin from ... breast cancer. Terry Kalley, founder of the ... the decision, saying, "While this vote is disappointing, it ...
... Mass., June 29, 2011 NxStage® Medical, Inc. (Nasdaq: ... dialysis products, announced that it has entered into a ... move its corporate headquarters to the revitalized historic mill ... Street, Lawrence, MA.  The move, which is expected to ...
Cached Medicine Technology:Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List 2NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA 2
(Date:11/26/2014)... (HealthDay News) -- Teens prescribed anti-anxiety or sleep ... drugs than other teens, a new study warns. ... substance abuse assessments on teenagers before prescribing these ... and parents don,t realize the abuse potential," said ... University of Michigan School of Nursing. "These drugs ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
(Date:11/24/2014)... November 24, 2014 The Healthy Skin ... reviews of affordable skin care products, recently announced its ... offers readers a wide variety of articles, tips, and ... as organic skincare alternatives. , According to Emily Lataille, ... main content includes thoroughly researched reviews, tips for the ...
(Date:11/24/2014)... 2014 Abington Health is ... has joined The Neurology Group and has been named ... , A graduate of Vinnica Medical University in ... Einstein Medical Center in Philadelphia and completed a fellowship ... Center at Weill Cornell Medical College. Ternopolska is board ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Recently, SweetDressy.com, ... industry, unveiled its new collection of 2014 Evening Dresses. ... now. According to the company’s marketing manager, the special ... http://www.sweetdressy.com/evening-dresses.html for more. , Sweetdressy.com has been working ... pleased to unveil the latest designs. Their new dresses ...
Breaking Medicine News(10 mins):Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
... (October 28, 2010) University of Minnesota Medical School ... a correlation between increased circuit activity in the right ... triggered by post traumatic stress disorder (PTSD). The ... neural activity, its impact and its manifestation is the ...
... News) -- Improving mothers, literacy skills may boost the ... study. U.S. researchers concluded that a mother,s reading ... critical factor influencing her children,s future academic success, even ... neighborhood income. For their study, the researchers examined ...
... American Academy of Pediatrics (AAP) recommends that parents limit combined ... 2 hours per day for preschool-age children. In a ... Pediatrics , researchers found that many children are exposed to ... with 66% exceeding the recommended daily amount. According to ...
... opinion polls, including newly released data, shows that those who ... in 2010 and those who say they intend to vote ... of what they want the future of health reform legislation ... in Congress on this issue. Nearly three-fourths (73%) ...
... Oct. 27 (HealthDay News) -- When it comes to feelings, ... People tend to have worse and more intense views on ... that have already taken place. The observation touches upon ... people apparently take more extreme positions regarding events that have ...
... evolution in action in cancer cells. They show the ... only is cancer genetically different between different patients, but ... has acquired distinct mutations. Effectively, ten different ... tumours. The complexity of pancreatic cancer genetics uncovered in ...
Cached Medicine News:Health News:U of M researchers identify possible key to treating, understanding post-traumatic stress disorder 2Health News:Moms' Literacy Pivotal to Kids' Academic Success 2Health News:New study suggests most preschool-age children exceed daily screen time recommendations 2Health News:Prospective voters and the new health care law 2Health News: Future Seems to Be Viewed More Harshly Than Past 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 3
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... It is designed for ... the surgeon greater freedom in ... 3-point rigid skeletal fixation is ... lateral, or sitting positions. Craniotomies ...
Medicine Products: